OCT 12, 2021 5:30 AM PDT

Tiny Fragments of RNA in the Blood Signal Dementia Risk

WRITTEN BY: Tara Fernandez

Scientists have discovered a novel biomarker in the blood that acts as an early warning sign for dementia: microRNA. These small, single-stranded RNA molecules are a distinct class of biological regulators that orchestrate the way genes are expressed, influencing many complex processes throughout the body.

In a study featured in EMBO Molecular Medicine, researchers led by André Fischer from the German Center for Neurodegenerative Diseases were motivated by finding biological red flags that can signal the potential for dementia onset long before the symptoms begin. 

“Presently, diagnosis happens far too late to even have a chance for effective treatment,” said Fischer. “If dementia is detected early, the odds of positively influencing the course of the disease increase.”

The team used a variety of experimental approaches in their study: animal models, cell cultures, and the analyses of clinical data from both healthy individuals and those with mild cognitive impairment. 

A deep dive revealed a clear pattern—levels of three microRNAs were closely linked to mental fitness levels. Fischer and colleagues also found that patients who had high levels of this biomarker in their blood samples had a 90 percent chance of going on to receive an Alzheimer’s diagnosis within two years. The team estimates that the presence of these microRNAs in circulation is indicative of dementia development within a two- to five-year timeframe.

Interestingly, the three microRNAs are not just clinical biomarkers but also have the potential to be drug targets to slow the neurodegenerative process. Experiments in mouse models of dementia revealed that drugs that specifically blocked these microRNA improved the animals’ learning abilities. “We’ve observed this in mice with age-related mental deficits, as well as in mice with brain damage similar to that occurring in Alzheimer’s disease,” said Fischer.

Ongoing work by the team is focused on translating their findings into a practical, low-cost, easy-to-use test for the microRNA signatures that doctors could deploy during routine medical checkups to catch dementia in their patients earlier.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 10, 2021
Clinical & Molecular DX
Noninvasive Device Warns When Wounds Are Bleeding
MAY 10, 2021
Noninvasive Device Warns When Wounds Are Bleeding
Patients with kidney failure have to undergo hemodialysis—a process where a dialysis machine takes the place of ki ...
JUN 08, 2021
Genetics & Genomics
Primers and Probes to Assay for SARS-CoV-2 Variants in Research Samples
JUN 08, 2021
Primers and Probes to Assay for SARS-CoV-2 Variants in Research Samples
Today, many scientists are investigating SARS-CoV-2 variants in their research projects. In order to facilitate screenin ...
JUN 16, 2021
Clinical & Molecular DX
Rapid Screening Tool Provides Insights on Brain Health
JUN 16, 2021
Rapid Screening Tool Provides Insights on Brain Health
Scientists at King’s College London have identified a single biomarker that can be used to diagnose a range of neu ...
JUL 29, 2021
Drug Discovery & Development
A low-cost drug for the treatment of hepatitis.
JUL 29, 2021
A low-cost drug for the treatment of hepatitis.
      The viral disease, Hepatitis C, is known as a silent killer. Hepatitis C is easily spread thro ...
SEP 16, 2021
Clinical & Molecular DX
Medical Opinions Are Often Divided, but Tech Can Bring Them Together
SEP 16, 2021
Medical Opinions Are Often Divided, but Tech Can Bring Them Together
Patients place their faith in medical professionals for making sound clinical decisions based on their diagnoses. But wh ...
SEP 16, 2021
Drug Discovery & Development
A shot for sore eyes: a novel injectable drug to treat age-related vision loss
SEP 16, 2021
A shot for sore eyes: a novel injectable drug to treat age-related vision loss
According to the Population Reference Bureau, 40 million people in the United States are aged 65 and older. This nu ...
Loading Comments...